Physician

Matthew Rion Zibelman, M.D.

According to 2025 Medicare claims, Matthew Zibelman, M.D. (NPI: 1902002215) practices hematopoietic cell transplantation and cellular therapy in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Philadelphia, PA. This provider's primary affiliated billing organization is TEMPLE FACULTY PRACTICE PLAN, INC (NPI: 1417430166; TIN: 831002191) and primary practice location at 19111-2434. Zibelman is affiliated with the Keystone ACO (ACO ID: A1552) and Trinity Health Integrated Care (ACO ID: A3454), participating under the MSSP model.

Zibelman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 230 traditional Medicare patients, billed 659 HCPCS/CPT codes, and received $61,787 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,723 prescription claims across 223 beneficiaries totaling $4,251,453 in drug costs, led by Xtandi (Enzalutamide). Open Payments data shows 31 records totaling $406,632. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $7,124 to $61,787. Similarly, Part D prescription costs have risen steadily, from $46,464 to $4,251,453. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.